​

​More than 90% of drug candidates fail in clinical trials, often after years of investment and billions in cost. The fundamental problem is not a lack of innovation, but a lack of predictive systems that accurately reflect human biology before clinical testing begins.

​

CSTEAM biotechnology is building a new foundation for drug development. We design predictive biochip platforms that determine whether a drug will succeed or fail—before it enters clinical trials. By integrating modular microfluidic biochips, multi-scale biological models, and data-driven analysis, we recreate human-relevant biological systems in a controlled and reproducible environment. Our platform reconstructs the complex interactions between tumor cells, immune systems, vascular structures, and the microenvironment. This allows dynamic evaluation of drug efficacy, safety, and resistance under conditions that closely resemble human physiology. Instead of relying on simplified or non-predictive models, we provide a system that captures the true complexity of biological response.

 

CSTEAM biotechnology focuses on antibody therapeutics and cell-based immunotherapies, including CAR-T and CAR-NK, where clinical success is often unpredictable. By enabling early identification of failure signals and high-confidence candidates, our technology reduces development risk and accelerates decision-making for biotech and pharmaceutical partners.

 

We are not building tools. We are building the system that decides which drugs succeed.

​